➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
McKinsey
Baxter
AstraZeneca
Express Scripts

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,046,056

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,046,056
Title:Glycotargeting therapeutics
Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
Inventor(s): Hubbell; Jeffrey A. (Chicago, IL), Wilson; David Scott (Lausanne, CH)
Assignee: Ecole Polytechnique Federale de Lausanne (EPFL) (Lausanne, CH)
Application Number:15/185,564
Patent Claims:1. A composition comprising a compound of Formula 1: XY--Z]L Formula 1 where: m is an integer from about 1 to 100; X comprises an antigen against which a patient develops an unwanted immune response; Y comprises ##STR00082## where: the left bracket "(" indicates the bond between X and Y; the bottom bracket and ")" indicates the bond between Y and Z; n is an integer from about 1 to 100; R.sup.9 is --CH.sub.2-- or --CH.sub.2--CH.sub.2--C(CH.sub.3)(CN)--; and W represents a polymer of the same W.sup.1 group, or W is a copolymer or a random copolymer of the same or different W.sup.1 and W.sup.2 groups, where: ##STR00083## where: p is an integer from 2 to about 150; R.sup.9 is a direct bond, --C(O)--NH--CH.sub.2--CH.sub.2--, or --C(O)--NH--(CH.sub.2--CH.sub.2--O--).sub.t--CH.sub.2--CH.sub.2--; t is an integer from 1 to 5; and R.sup.10 is an aliphatic group, an alcohol or an aliphatic alcohol; and Z comprises one or more liver-targeting moieties.

2. The composition of claim 1 where Z comprises galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine or N-acetylglucosamine.

3. The composition of claim 2, wherein Z is the beta anomer.

4. The composition of claim 2 comprising Z conjugated at its C1, C2 or C6 to Y.

5. The composition of claim 1 where Y is prepared using a linker precursor selected from N-hydroxysuccinamidyl-based linkers, malaemide-based linkers, vinylsulfone-based linkers, pyridyl di-thiol-poly(ethylene glycol)-based linkers, pyridyl di-thiol-based linkers, n-nitrophenyl carbonate-based linkers, NHS-ester-based linkers, and nitrophenoxy poly(ethylene glycol)ester-based linkers.

6. The composition of claim 1, wherein X is a synthetic self-antigen and the unwanted immune response is an autoimmune response.

7. The composition of claim 1, wherein X is selected from the group consisting of myelin oligodendrocyte glycoprotein, myelin proteolipid protein, and myelin basic protein and wherein the unwanted immune response is associated with multiple sclerosis.

8. The composition of claim 1, wherein X is selected from the group consisting of insulin, proinsulin, and preproinsulin and wherein the unwanted immune response is associated with type 1 diabetes mellitus.

9. The composition of claim 1, wherein X is a therapeutic agent selected from the group consisting of Factor VIII and Factor IX.

10. The composition of claim 1, wherein X is a therapeutic agent selected from the group consisting of asparaginase and uricase.

11. The composition of claim 1, wherein X is a is a food antigen selected from the group consisting of: conarachin (Ara h 1), allergen II (Ara h 2), arachis agglutinin, conglutin (Ara h 6), a-lactalbumin (ALA), lactotransferrin, Pen a 1 allergen (Pen a 1), allergen Pen m 2 (Pen m 2), tropomyosin fast isoform, high molecular weight glutenin, low molecular weight glutenin, alpha-gliadin, gamma-gliadin, omega-gliadin, hordein, secalin, and avenin.

12. The composition of claim 1, wherein administration of the composition to the subject results in a greater degree of proliferation of antigen-specific T cells as compared to proliferation of antigen-specific T cells resulting from administration of the antigen alone.

13. The composition of claim 3, wherein administration of the composition to the subject results in a greater expression of exhaustion markers or markers of apoptosis on antigen-specific T cells as compared to expression of exhaustion markers or markers of apoptosis on antigen-specific T cells resulting from administration of the antigen alone.

14. A composition for inducing tolerance to an antigen to which a subject develops an unwanted immune response, the composition comprising a compound of Formula 1: XY--Z]L Formula 1 where: m is an integer from about 1 to 10; X comprises an antigen to which patients develop an unwanted immune response, wherein the antigen is a food antigen, a therapeutic agent, or a self-antigen; Y is: ##STR00084## wherein: the left bracket "(" indicates a bond to X; the bottom bracket and ")" indicates the bond between Y and Z; n is an integer from about 1 to 100; R.sup.8 is --CH.sub.2--CH.sub.2--C(CH.sub.3)(CN)--; W represents a polymer of the same W.sup.1 group, or W is a copolymer or a random copolymer of the same or different W.sup.1 and W.sup.2 groups, where: ##STR00085## where: p is an integer from 2 to about 150; where present R.sup.9 is a direct bond, --C(O)--NH--CH.sub.2--CH.sub.2--, or --C(O)--NH--(CH.sub.2--CH.sub.2--O--).sub.t--CH.sub.2--CH.sub.2--; t is an integer from 1 to 5; and R.sup.10 is an aliphatic group, an alcohol, or an aliphatic alcohol; and Z comprises one or more of galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, or N-acetyl glucosamine.

15. The composition of claim 14, wherein m is 1 to 3.

16. The composition of claim 14, wherein X is selected from the group consisting of myelin oligodendrocyte glycoprotein, myelin proteolipid protein, and myelin basic protein and wherein the unwanted immune response is associated with multiple sclerosis.

17. The composition of claim 14, wherein X is a is a food antigen selected from the group consisting of: conarachin (Ara h 1), allergen II (Ara h 2), arachis agglutinin, conglutin (Ara h 6), a-lactalbumin (ALA), lactotransferrin, Pen a 1 allergen (Pen a 1), allergen Pen m 2 (Pen m 2), tropomyosin fast isoform, high molecular weight glutenin, low molecular weight glutenin, alpha-gliadin, gamma-gliadin, omega-gliadin, hordein, secalin, and avenin.

18. The composition of claim 1, wherein m is 1 to 3; R.sup.8 is --CH.sub.2--CH.sub.2--C(CH.sub.3)(CN)--; R.sup.9 is --C(O)--NH--(CH.sub.2--CH.sub.2--O--).sub.t--CH.sub.2--CH.sub.2--; t is 1; R.sup.10 is CH.sub.2CH.sub.2OH; and Z comprises a liver-targeting moiety comprising one or more of galactose, galactosamine, N-acetylgalactosamine, glucose, glucosamine, and N-acetylglucosamine.

19. The composition of claim 14, wherein X is selected from the group consisting of insulin, proinsulin, and preproinsulin and wherein the unwanted immune response is associated with type 1 diabetes mellitus.

20. The composition of claim 14, wherein X is a self-antigen and the unwanted immune response is an autoimmune response.

21. The composition of claim 14, wherein Z is the beta anomer.

22. The composition of claim 14 comprising Z conjugated at its C1, C2 or C6 to Y.

23. The composition of claim 14, wherein X is a therapeutic agent selected from the group consisting of Factor VIII and Factor IX.

24. The composition of claim 14, wherein X is a therapeutic agent selected from the group consisting of asparaginase and uricase.

25. The composition of claim 14, wherein m is 1 to 3; R.sup.9 is --CH.sub.2--CH.sub.2--(O--CH.sub.2--CH.sub.2).sub.t--NH--C(O)--; t is 1; and R.sup.19 is CH.sub.2CH.sub.2OH.

Details for Patent 10,046,056

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10 ⤷  Free Forever Trial Ecole Polytechnique Federale de Lausanne (EPFL) (Lausanne, CH) 2034-02-21 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,046,056

Country Patent Number Estimated Expiration
Australia 2015233084 ⤷  Free Forever Trial
Australia 2016325073 ⤷  Free Forever Trial
Australia 2021201504 ⤷  Free Forever Trial
Brazil 112016019274 ⤷  Free Forever Trial
Brazil 112018005409 ⤷  Free Forever Trial
Canada 2946064 ⤷  Free Forever Trial
Canada 2998066 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
AstraZeneca
Johnson and Johnson
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.